GlaxoSmithKline ready to supply Biota’s Relenza to meet CDC recommendations
Chronic obstructive pulmonary disease (COPD) has a higher hospitalization rate and a higher hospital readmission rate than heart failure, angina, and other serious chronic diseases. Now, new survey results confirm that COPD affects many more Canadians than previously estimated (1.5 million) - and that 69 per cent of Canadians have not heard of COPD. In
Full Post: Chronic obstructive pulmonary disease sending more people to hospital
GlaxoSmithKline (GSK) is prepared to respond to public health needs for Relenza (zanamivir) Inhalation Powder this flu season following a Health Alert Advisory issued by the Centers for Disease Control and Prevention (CDC).
Relenza is a preferred medication in the CDC-issued interim recommendations for all circulating subtypes of influenza virus.
This interim guidance is based on early and limited data from the current influenza season that has detected a significant increase in the proportion of influenza A (H1N1) viruses that are resistant to Tamiflu (oseltamivir). It is not possible to predict how common the influenza A (H1N1) viruses will be during the remainder of the 2008-2009 flu season. All tested influenza virus subtypes have shown no resistance to Relenza. Clinical significance cannot be inferred from this surveillance data.
GSK has sufficient supply available of Relenza to meet 2008-2009 influenza season needs. Pharmacies can obtain Relenza from their wholesalers.
Antiviral resistance is a potentially significant issue when considering widespread use during the peak months of influenza season. GSK is committed to making Relenza available. However, this emergence also underscores the importance of receiving an annual influenza vaccination, as recommended by the CDC’s Advisory Committee on Immunization Practices.
CDC’s interim recommendations on the use of influenza antiviral medications in the United States for the 2008-2009 flu season was issued in a Health Alert Advisory on December 19th, 2008. Revised guidance is available at www.cdc.gov/flu .
Relenza is a medicine for the treatment of influenza and for reducing the chance of getting the flu in community and household settings. It belongs to a group of medicines called neuraminidase inhibitors. These medications attack the influenza virus and prevent it from spreading inside your body. Relenza treats the cause of influenza at its source, rather than simply masking the symptoms. Relenza is delivered via inhalation using a diskhaler. Step-by-step instructions for proper use of the diskhaler are available at www.Relenza.com, including a short instruction video.
Relenza is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease).
Serious cases of bronchospasm, including fatalities, have been reported during treatment with Relenza in patients with and without underlying airways disease. Many of these cases were reported during postmarketing and causality was difficult to assess.
If use of Relenza is considered for a patient with underlying airways disease, the potential risks and benefits should be carefully weighed. Use in these patients should be done only under conditions of careful monitoring or respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators.
Discontinue Relenza and initiate appropriate treatment if an allergic reaction occurs or is suspected.
Patients with influenza, particularly pediatric patients, may be at an increased risk of seizures, confusion, or abnormal behavior early in their illness. Monitor for signs of abnormal behavior.
Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions.
Relenza has not been proven effective for prophylaxis of influenza in the nursing home setting.
Relenza is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control’s Immunization Practices Advisory Committee.
Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Relenza.
Workers age 50-64 who received influenza vaccine lost substantially fewer days of work and worked fewer days while ill, according to a new study in the Feb. 1 issue of Clinical Infectious Diseases, now available online. Given the concerns about antiviral drug resistance among this year’s flu strains, the study highlights the importance of vaccination
Full Post: Influenza vaccine helps 50-64 year olds stay at work
The National Association of County and City Health Officials (NACCHO) has announced a donation of up to one million doses of FluMist (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations. NACCHO will make these donated doses of vaccine available to selected state
Full Post: NACCHO to donate up to one million doses of FluMist
College students who are vaccinated against influenza appear less likely to develop flu-like illnesses, require related health care visits or experience impairments in academic performance during flu season, according to a report in the December issue of Archives of Pediatrics & Adolescent Medicine. An estimated 9 percent to 20 percent of college and university students
Full Post: College students vaccinated against influenza less likely to develop flu-like illnesses
A new University of Colorado at Boulder study shows the resistance of the avian flu virus to a major class of antiviral drugs is increasing through positive evolutionary selection, with researchers documenting the trend in more than 30 percent of the samples tested. The avian flu, an Influenza A subtype dubbed H5N1, is evolving a
Full Post: Bird flu becoming more resistant to antivirals
The research council FORMAS, Sweden, has granted 5.9 million SEK to a new research project that will study the environmental fate and effects of the anti-viral drug Tamiflu on the development on influenza resistance. Tamiflu is being stockpiled all over the world for use in fighting the next influenza pandemic. However, there are growing signs
Full Post: Study looks at Tamiflu resistance in influenza viruses caused by environmental contamination